Abstract
The predominance of insulin resistance, T2D linked pancreatic cancer has increased throughout the world. The insulin/IGF signaling pathway related to insulin resistance, T2D and pancreatic cancer has been described. In this context, we have demonstrated the role of miRNAs in cancer progression and control of miRNAs in insulin/IGF signaling pathway, and pancreatic cancer. In this paper, an overview was depicted about the role of following miRNAs in pancreatic development and insulin secretion (miR-375, miR-7, miR-124a2, miR-195, miR-126, miR-9, miR-96, miR-34a); insulingrowth factor-1 receptor expression (miR-7, miR-139, miR-145, miR-1); the diabetes-associated pancreatic cancer pathway genes such as IRS, PI3K, AKT/PKB (miR-128a, miR-19a, miR-21, miR-29 a/b/c); mTOR protein regulation (miR- 99, miR-21, miR-126, and miR-146a) etc. At last, we have also explained the role of miRNAs in diagnostic marker (miR- 200, miR-21, miR-103, miR-107, and miR-155) and as a therapeutic modulator (miR-34, miR-21, miR-221, and miR-101) in pancreatic cancer.
Keywords: miRNA, insulin/IGF-mTOR signaling pathway, insulin resistance, type-2 diabetes, pancreatic cancer.
Current Drug Targets
Title:miRNAs in Insulin Resistance and Diabetes-Associated Pancreatic Cancer: The ‘Minute and Miracle’ Molecule Moving as a Monitor in the ‘Genomic Galaxy’
Volume: 14 Issue: 10
Author(s): Chiranjib Chakraborty, George Priya Doss. C and Sanghamitra Bandyopadhyay
Affiliation:
Keywords: miRNA, insulin/IGF-mTOR signaling pathway, insulin resistance, type-2 diabetes, pancreatic cancer.
Abstract: The predominance of insulin resistance, T2D linked pancreatic cancer has increased throughout the world. The insulin/IGF signaling pathway related to insulin resistance, T2D and pancreatic cancer has been described. In this context, we have demonstrated the role of miRNAs in cancer progression and control of miRNAs in insulin/IGF signaling pathway, and pancreatic cancer. In this paper, an overview was depicted about the role of following miRNAs in pancreatic development and insulin secretion (miR-375, miR-7, miR-124a2, miR-195, miR-126, miR-9, miR-96, miR-34a); insulingrowth factor-1 receptor expression (miR-7, miR-139, miR-145, miR-1); the diabetes-associated pancreatic cancer pathway genes such as IRS, PI3K, AKT/PKB (miR-128a, miR-19a, miR-21, miR-29 a/b/c); mTOR protein regulation (miR- 99, miR-21, miR-126, and miR-146a) etc. At last, we have also explained the role of miRNAs in diagnostic marker (miR- 200, miR-21, miR-103, miR-107, and miR-155) and as a therapeutic modulator (miR-34, miR-21, miR-221, and miR-101) in pancreatic cancer.
Export Options
About this article
Cite this article as:
Chakraborty Chiranjib, Doss. C Priya George and Bandyopadhyay Sanghamitra, miRNAs in Insulin Resistance and Diabetes-Associated Pancreatic Cancer: The ‘Minute and Miracle’ Molecule Moving as a Monitor in the ‘Genomic Galaxy’, Current Drug Targets 2013; 14 (10) . https://dx.doi.org/10.2174/13894501113149990182
DOI https://dx.doi.org/10.2174/13894501113149990182 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Volatilome Metabolomics and Databases, Recent Advances and Needs
Current Metabolomics Polo-Like Kinase 1 as a Potential Therapeutic Target for Osteosarcoma
Current Pharmaceutical Design Chemically Modified Gelatin as Biomaterial in the Design of New Nanomedicines
Medicinal Chemistry Current Prodrug Strategies for the Delivery of Nucleotides into Cells
Drug Design Reviews - Online (Discontinued) Inhibition of Calcium Oxalate Nephrotoxicity with Cymbopogon Schoenanthus (Al-Ethkher)
Drug Metabolism Letters High Mobility Group Box-1 (HMGB1): A Potential Target in Therapeutics
Current Drug Targets Safer, Greener, and More Facile Alternatives for Synthesis with Organic Azides
Current Organic Synthesis Biochemical, Biomedical and Metabolic Aspects of Imidazole-Containing Dipeptides with the Inherent Complexity to Neurodegenerative Diseases and Various States of Mental Well-Being: A Challenging Correction and Neurotherapeutic Pharmaceutical Biotechnology for Treating Cognitive Deficits, Depression and Intellectual Disabilities
Current Pharmaceutical Biotechnology Old Strategies and New Perspectives in Modulating the Endocannabinoid System
Current Bioactive Compounds A Systematic Review of the Potential Herbal Sources of Future Drugs Effective in Oxidant-Related Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Anticancer Peptides and Proteins: A Panoramic View
Protein & Peptide Letters Musculoskeletal Adverse Drug Reactions: A Review of Literature and Data from ADR Spontaneous Reporting Databases
Current Drug Safety RECKing MMP: Relevance of Reversion-inducing Cysteine-rich Protein with Kazal Motifs as a Prognostic Marker and Therapeutic Target for Cancer (A Review)
Anti-Cancer Agents in Medicinal Chemistry Plant Glycosides and Aglycones Displaying Antiproliferative and Antitumour Activities – A Review
Current Bioactive Compounds Neurotransmitters and Chemokines Regulate Tumor Cell Migration: Potential for a New Pharmacological Approach to Inhibit Invasion and Metastasis Development
Current Pharmaceutical Design The Effect of Dihydroartemisinin on the Malignancy and Epithelial-Mesenchymal Transition of Gastric Cancer Cells
Current Pharmaceutical Biotechnology Perspectives on New Synthetic Curcumin Analogs and their Potential Anticancer Properties
Current Pharmaceutical Design Redox Environment and its Meaning for Breast Cancer Cells Fate
Current Cancer Drug Targets Regulation of Bcl-2 Family Proteins by Posttranslational Modifications
Current Molecular Medicine Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies
Current Cancer Drug Targets